TNFSF9 expression in primary biliary cirrhosis and its clinical significance

Cytokine

Volumn 50, Issue 3, 2010, Pages 311-316

  Xia, Rong ^a   Tang, Yujie ^b   Huang, Yuanlan ^b   Yao, Dingkang ^b   Zhou, Ye ^b   Chen, Bo ^b   Chen, Yan ^b   Chen, Sunxiao ^b   Deng, Anmei ^b   Zhong, Renqian ^b  

^a FUDAN UNIVERSITY   (China)

^b SECOND MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Interlectin 18; Primary biliary cirrhosis; Tumor necrosis superfamily member 9

Indexed keywords

BILIRUBIN; GAMMA GLUTAMYLTRANSFERASE; INTERLEUKIN 18; LYMPHOCYTE ANTIGEN; TUMOR NECROSIS FACTOR SUPERFAMILY MEMBER 9; UNCLASSIFIED DRUG;

ADULT; APOPTOSIS; ARTICLE; CELL ISOLATION; CELL PROLIFERATION; CONTROLLED STUDY; DISEASE COURSE; DISEASE SEVERITY; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION; GENETIC VARIABILITY; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIMARY BILIARY CIRRHOSIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; PROTHROMBIN TIME; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SURVIVAL RATE;

4-1BB LIGAND; CASE-CONTROL STUDIES; DISEASE PROGRESSION; FEMALE; GAMMA-GLUTAMYLTRANSFERASE; GENE EXPRESSION REGULATION; HUMANS; INTERLEUKIN-18; LEUKOCYTES, MONONUCLEAR; LIVER CIRRHOSIS, BILIARY; MALE; MIDDLE AGED; RISK FACTORS; RNA, MESSENGER; STATISTICS, NONPARAMETRIC;

EID: 77952469970     PISSN: 10434666     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cyto.2010.02.001     Document Type: Article

References (41)

1. Jones D.E. Pathogenesis of primary biliary cirrhosis. Clin Liver Dis 2008, 12:305-321. viii.
2. Shimoda S., Harada K., Niiro H., Yoshizumi T., Soejima Y., Taketomi A., et al. Biliary epithelial cells and primary biliary cirrhosis: the role of liver-infiltrating mononuclear cells. Hepatology 2008, 47:958-965.
3. Nikkila K., Nissinen M.J., Gylling H., Isoniemi H., Miettinen T.A. Serum sterols in patients with primary biliary cirrhosis and acute liver failure before and after liver transplantation. J Hepatol 2008, 49:936-945.
4. Abe M., Onji M. Natural history of primary biliary cirrhosis. Hepatol Res 2008, 38:639-645.
5. Kita H. Autoreactive CD8-specific T-cell response in primary biliary cirrhosis. Hepatol Res 2007, 37(Suppl. 3):S402-S405.
6. Rong G., Zhou Y., Xiong Y., Zhou L., Geng H., Jiang T., et al. Imbalance between T helper type 17 and T regulatory cells in patients with primary biliary cirrhosis: the serum cytokine profile and peripheral cell population. Clin Exp Immunol 2009, 156:217-225.
7. Lan R.Y., Salunga T.L., Tsuneyama K., Lian Z.X., Yang G.X., Hsu W., et al. Hepatic IL-17 responses in human and murine primary biliary cirrhosis. J Autoimmun 2009, 32:43-51.
8. Leifeld L., Cheng S., Ramakers J., Dumoulin F.L., Trautwein C., Sauerbruch T., et al. Imbalanced intrahepatic expression of interleukin 12, interferon gamma, and interleukin 10 in fulminant hepatitis B. Hepatology 2002, 36:1001-1008.
9. Lleo A., Invernizzi P., Mackay I.R., Prince H., Zhong R.Q., Gershwin M.E. Etiopathogenesis of primary biliary cirrhosis. World J Gastroenterol 2008, 14:3328-3337.
10. Yamano T., Higashi T., Nouso K., Nakatsukasa H., Kariyama K., Yumoto E., et al. Serum interferon-gamma-inducing factor/IL-18 levels in primary biliary cirrhosis. Clin Exp Immunol 2000, 122:227-231.
11. Shimoda S., Ishikawa F., Kamihira T., Komori A., Niiro H., Baba E., et al. Autoreactive T-cell responses in primary biliary cirrhosis are proinflammatory whereas those of controls are regulatory. Gastroenterology 2006, 131:606-618.
12. Fickert P., Trauner M. When lightning strikes twice. the plot thickens for a dual role of the anion exchanger 2 (AE2/SLC4A2) in the pathogenesis and treatment of primary biliary cirrhosis. J Hepatol 2009, 50:633-635.
13. Kawano A., Shimoda S., Kamihira T., Ishikawa F., Niiro H., Soejima Y., et al. Peripheral tolerance and the qualitative characteristics of autoreactive T cell clones in primary biliary cirrhosis. J Immunol 2007, 179:3315-3324.
14. Ishibashi H., Shimoda S., Gershwin M.E. The immune response to mitochondrial autoantigens. Semin Liver Dis 2005, 25:337-346.
15. Yoneyama K., Yamazaki M., Kogo M., Kiuchi Y., Shibata M., Imawari M. Prognostic factors of primary biliary cirrhosis detected by health screening. Minerva Gastroenterol Dietol 2006, 52:97-105.
16. Rieger R., Leung P.S., Jeddeloh M.R., Kurth M.J., Nantz M.H., Lam K.S., et al. Identification of 2-nonynoic acid, a cosmetic component, as a potential trigger of primary biliary cirrhosis. J Autoimmun 2006, 27:7-16.
17. Honda Y., Yamagiwa S., Matsuda Y., Takamura M., Ichida T., Aoyagi Y. Altered expression of TLR homolog RP105 on monocytes hypersensitive to LPS in patients with primary biliary cirrhosis. J Hepatol 2007, 47:404-411.
18. Langstein J., Becke F.M., Sollner L., Krause G., Brockhoff G., Kreutz M., et al. Comparative analysis of CD137 and LPS effects on monocyte activation, survival, and proliferation. Biochem Biophys Res Commun 2000, 273:117-122.
19. Zhang N., Sadun R.E., Arias R.S., Flanagan M.L., Sachsman S.M., Nien Y.C., et al. Targeted and untargeted CD137L fusion proteins for the immunotherapy of experimental solid tumors. Clin Cancer Res 2007, 13:2758-2767.
20. Lin G.H., Sedgmen B.J., Moraes T.J., Snell L.M., Topham D.J., Watts T.H. Endogenous 4-1BB ligand plays a critical role in protection from influenza-induced disease. J Immunol 2009, 182:934-947.
21. Kober J., Leitner J., Klauser C., Woitek R., Majdic O., Stockl J., et al. The capacity of the TNF family members 4-1BBL, OX40L, CD70, GITRL, CD30L and LIGHT to costimulate human T cells. Eur J Immunol 2008, 38:2678-2688.
22. Lin X., Zhou C., Wang S., Wang D., Ma W., Liang X., et al. Enhanced antitumor effect against human telomerase reverse transcriptase (hTERT) by vaccination with chemotactic-hTERT gene-modified tumor cell and the combination with anti-4-1BB monoclonal antibodies. Int J Cancer 2006, 119:1886-1896.
23. Liu G.Z., Gomes A.C., Putheti P., Karrenbauer V., Kostulas K., Press R., et al. Increased soluble 4-1BB ligand (4-1BBL) levels in peripheral blood of patients with multiple sclerosis. Scand J Immunol 2006, 64:412-419.
24. Hentschel N., Krusch M., Kiener P.A., Kolb H.J., Salih H.R., Schmetzer H.M. Serum levels of sCD137 (4-1BB) ligand are prognostic factors for progression in acute myeloid leukemia but not in non-Hodgkin's lymphoma. Eur J Haematol 2006, 77:91-101.
25. Yang J., Park O.J., Lee Y.J., Jung H.M., Woo K.M., Choi Y. The 4-1BB ligand and 4-1BB expressed on osteoclast precursors enhance RANKL-induced osteoclastogenesis via bi-directional signaling. Eur J Immunol 2008, 38:1598-1609.
26. Jung H.W., Choi S.W., Choi J.I., Kwon B.S. Serum concentrations of soluble 4-1BB and 4-1BB ligand correlated with the disease severity in rheumatoid arthritis. Exp Mol Med 2004, 36:13-22.
27. Xu K., Li C., Pan X., Du B. Study of relieving graft-versus-host disease by blocking CD137-CD137 ligand costimulatory pathway in vitro. Int J Hematol 2007, 86:84-90.
28. Choi B.K., Asai T., Vinay D.S., Kim Y.H., Kwon B.S. 4-1BB-mediated amelioration of experimental autoimmune uveoretinitis is caused by indoleamine 2,3-dioxygenase-dependent mechanisms. Cytokine 2006, 34:233-242.
29. Shin H.H., Lee E.A., Kim S.J., Kwon B.S., Choi H.S. A signal through 4-1BB ligand inhibits receptor for activation of nuclear factor-kappaB ligand (RANKL)-induced osteoclastogenesis by increasing interferon (IFN)-beta production. FEBS Lett 2006, 580:1601-1606.
30. Ye J.X., Zhang Y.T., Zhang X.G., Ren D.M., Chen W.C. Recombinant attenuated Salmonella harboring 4-1BB ligand gene enhances cellular immunity. Vaccine 2009, 27:1717-1723.
31. Weinberg A.D., Montler R. Modulation of TNF receptor family members to inhibit autoimmune disease. Curr Drug Targets Inflamm Allergy 2005, 4:195-203.
32. Heathcote E.J. Management of primary biliary cirrhosis. The American Association for the Study of Liver Diseases practice guidelines. Hepatology 2000, 31:1005-1013.
33. Murtaugh P.A., Dickson E.R., Van Dam G.M., Malinchoc M., Grambsch P.M., Langworthy A.L., et al. Primary biliary cirrhosis: prediction of short-term survival based on repeated patient visits. Hepatology 1994, 20:126-134.
34. Kim Y., Strehl J.W., Gorschluter M., Ziske C., Schmidt-Wolf I.G. Prevention of lethal tumor growth and generation of long-lasting immunity in vivo using CD137L and interleukin-12 gene transfer. In vivo 2008, 22:337-343.
35. Xu D.P., Sauter B.V., Huang T.G., Meseck M., Woo S.L., Chen S.H. The systemic administration of Ig-4-1BB ligand in combination with IL-12 gene transfer eradicates hepatic colon carcinoma. Gene Ther 2005, 12:1526-1533.
36. Arenas F., Hervias I., Uriz M., Joplin R., Prieto J., Medina J.F. Combination of ursodeoxycholic acid and glucocorticoids upregulates the AE2 alternate promoter in human liver cells. J Clin Invest 2008, 118:695-709.
37. Wakabayashi K., Lian Z.X., Moritoki Y., Lan R.Y., Tsuneyama K., Chuang Y.H., et al. IL-2 receptor alpha(-/-) mice and the development of primary biliary cirrhosis. Hepatology 2006, 44:1240-1249.
38. Takii Y., Nakamura M., Ito M., Yokoyama T., Komori A., Shimizu-Yoshida Y., et al. Enhanced expression of type I interferon and toll-like receptor-3 in primary biliary cirrhosis. Lab Invest 2005, 85:908-920.
39. Harada K., Nakanuma Y. N.Y. Biliary innate immunity and cholangiopathy. Hepatol Res 2007, 37:S430-S437.
40. Mao T.K., Lian Z.X., Selmi C., Ichiki Y., Ashwood P., Ansari A.A., et al. Altered monocyte responses to defined TLR ligands in patients with primary biliary cirrhosis. Hepatology 2005, 42:802-808.
41. Gershwin M.E., Mackay I.R. The causes of primary biliary cirrhosis: convenient and inconvenient truths. Hepatology 2008, 47:737-745.